Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorvotuzumab Mertansine + Chemo in SCLC
NCT01237678Phase 2Terminated
- Sponsor
- ImmunoGen
- Start
- Nov 2010
- Primary completion
- May 2015
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 4
01
Overview
A Phase 2 trial of lorvotuzumab mertansine in small cell lung cancer (SCLC), sponsored by ImmunoGen. Started Nov 2010; status: terminated.
02
Drugs
lorvotuzumab mertansine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01237678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01237678.